Which is better, BVS or GMAB?

On the Buffett-Fit framework, Genmab A/S (GMAB) currently grades higher than BVS — 65/100 (C grade) vs 36/100 (D). That said, "better" depends on which framework you trust — BVS wins on Peter Lynch; GMAB wins on Warren Buffett, Benjamin Graham, Philip Fisher, Joel Greenblatt, Charlie Munger, and Terry Smith. The full pillar breakdown is on this page.

Should I buy BVS or GMAB?

This page is an educational comparison, not investment advice. Both BVS and GMAB are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is BVS better than GMAB for value investing?

On the Buffett-style value-investing framework, GMAB currently grades higher — 65/100 vs 36/100, a 29-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between BVS and GMAB on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). BVS currently scores 36/100 (D grade); GMAB scores 65/100 (C grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, BVS or GMAB?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. BVS and GMAB are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, BVS or GMAB?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are BVS and GMAB both Healthcare stocks?

Yes — both Bioventus Inc. (BVS) and Genmab A/S (GMAB) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this BVS vs GMAB comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Bioventus

Genmab A/S

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

BVS

Bioventus

Market cap

$628.7M

Sector

Healthcare

GMAB

Genmab A/S

Market cap

$16.5B

Sector

Healthcare

Overall winner

Genmab A/S GMAB

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	BVS	GMAB	Winner
Warren Buffett	36D	65C	GMAB
Benjamin Graham	52D	64C	GMAB
Philip Fisher	41D	48D	GMAB
Peter Lynch	29F	25F	BVS
Joel Greenblatt	26F	76B	GMAB
Charlie Munger	38D	68C	GMAB
Terry Smith	34F	71C	GMAB

Side-by-side metrics

Metric	BVS	GMAB
Market cap	$628.7M	$16.5B
P/E (TTM)	25.0x	6.2x
EV/EBIT	12.0x	12.0x
ROIC (TTM)	11.77%	43.78%
Gross margin	67.78%	93.88%
Net margin	4.94%	18.23%
Revenue CAGR 5y	7.15%	-18.45%
EPS CAGR 5y	-	-23.48%
Debt / Equity	0.1x	0.1x
Dividend yield	0.0%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

BVS leads on

Revenue CAGR 5y7.15%vs -18.45%+139%

GMAB leads on

Market cap$16.5Bvs $628.7M+96%
P/E (TTM)6.2xvs 25.0x+75%
ROIC (TTM)43.78%vs 11.77%+73%
Net margin18.23%vs 4.94%+73%

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Bioventus

Genmab A/S

Fit scores by strategy

Side-by-side metrics

Where each one wins

More like BVS

More like GMAB

Related on invest-like

Key terms in this analysis